Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2.

What was studied

This was a post hoc look at the SELECT-PsA 2 study. It tested upadacitinib 15 mg once daily in psoriatic arthritis (PsA). The patients had used one earlier TNF inhibitor (TNFi). They got upadacitinib or placebo by chance. Placebo patients switched to upadacitinib at week 24. Checks ran through 152 weeks. The team also looked at how long earlier TNFi use lasted. They also looked at early pain scores.

What they found

Of 195 patients, 90 got upadacitinib and 105 got placebo. At week 24, more upadacitinib patients met ACR20, ACR50, ACR70, and MDA criteria. Responses held or improved through week 152. Placebo patients who switched kept skin responses in different body areas. Results were generally similar whatever the length of earlier TNFi use. Lower pain early on, at weeks 2 and 12, predicted MDA at week 152. The abstract reports no new safety signals.

What it means for patients

The authors say upadacitinib 15 mg once daily showed sustained efficacy. They also call its safety profile acceptable. This was in PsA patients with one earlier TNFi. They say it held whatever the length of earlier TNFi use.

Why it is not certain yet

This was a post hoc analysis, so it was not planned in advance. The abstract does not say how many patients stayed in the study to week 152. The abstract does not give confidence intervals. Only patients with one earlier TNFi were studied.

Source

Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2.

We restate facts from the source record in our own words. The original wording belongs to its publisher.